Jonathan L. Kaufman
Emory University(US)Piedmont Cancer Institute(US)Lipella Pharmaceuticals (United States)(US)
Publications by Year
Research Areas
Multiple Myeloma Research and Treatments, Protein Degradation and Inhibitors, Cancer Treatment and Pharmacology, Chronic Lymphocytic Leukemia Research, Peptidase Inhibition and Analysis
Most-Cited Works
- → Widespread Genetic Heterogeneity in Multiple Myeloma: Implications for Targeted Therapy(2014)994 cited
- → Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma(2010)858 cited
- → Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial(2014)782 cited
- → Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma(2009)775 cited
- → Tyrosine Phosphorylation Inhibits PKM2 to Promote the Warburg Effect and Tumor Growth(2009)774 cited
- → Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial